LumiraDx to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Quarterly Conference Call on March 10

Rhea-AI Summary

LumiraDx (Nasdaq: LMDX) will release its fourth quarter and full year 2021 financial results on March 10, 2022. A conference call is scheduled for 8 AM Eastern Time that day to discuss the results and business highlights. The company, established in 2014, specializes in next-generation point-of-care diagnostics, offering over 30 tests for various health conditions. With more than 1600 employees globally, LumiraDx focuses on transforming healthcare delivery through innovative diagnostic solutions.

Positive

• Scheduled release of fourth quarter and full year 2021 financial results.
• Conference call to discuss business highlights, enhancing investor communication.

Negative

• None.

LONDON, March 3, 2022 /PRNewswire/ -- LumiraDx Limited  (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2021 financial results on Thursday, March 10, 2022. On the day of the release, LumiraDx will host a conference call and webcast at 8 AM Eastern Time to review the financial results and business highlights.

Event:	LumiraDx Fourth Quarter 2021 Financial Results Conference Call
Date:	Thursday, March 10, 2022
Time:	8:00 AM Eastern Time
Live Call/Webcast:	(844) 224-4100 (Domestic), (215) 372-9500 (International)
	Conference ID:  5877767
	https://investors.lumiradx.com/news-and-events/investor-calendar

A replay of the webcast will be available on the Investor's section of the company's website at investors.lumiradx.com shortly after the conclusion of the call. The webcast will be archived for one year.

About LumiraDx

LumiraDx (Nasdaq: LMDX) is a next-generation point of care diagnostics company that is transforming community-based healthcare. Founded in 2014, LumiraDx manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. LumiraDx diagnostic testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness as well as disease. LumiraDx has, on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform. In addition, LumiraDx has a comprehensive portfolio of fast, accurate, and cost-efficient COVID-19 testing solutions from the lab to point of need.
LumiraDx is based in the UK with more than 1600 employees worldwide.

Further information on LumiraDx and the LumiraDx Platform is available at www.lumiradx.com 

Contact:
Colleen McMillen
Colleen.McMillen@lumiradx.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lumiradx-to-announce-fourth-quarter-and-full-year-2021-financial-results-and-host-quarterly-conference-call-on-march-10-301495001.html

SOURCE LumiraDx

FAQ

When will LumiraDx announce its fourth quarter and full year 2021 financial results?

LumiraDx will announce its financial results on March 10, 2022.

What time is the LumiraDx financial results conference call?

The conference call is scheduled for 8 AM Eastern Time on March 10, 2022.

Where can I listen to the LumiraDx conference call?

You can listen to the call via live webcast, and a replay will be available on their investor website.

What does LumiraDx specialize in?

LumiraDx specializes in next-generation point-of-care diagnostics, offering over 30 tests.

Is LumiraDx publicly traded?

Yes, LumiraDx is publicly traded on the Nasdaq under the ticker LMDX.